PAKISTAN COUNTRY DATA

EPIDEMIC ESTIMATES			
	2010	2015	2019
New HIV infections			
New HIV infections (all ages)	14 000	19 000	25 000
	[13 000–16 000]	[17 000–21 000]	[23 000–27 000]
New HIV infections (0-14)	780	1200	1500
	[650–920]	[1000–1300]	[1300–1700]
New HIV infections (women, 15+)	3800	5100	6700
	[3300–4400]	[4500–5600]	[6100–7500]
New HIV infections (men, 15+)	9600	13 000	17 000
	[8500–11 000]	[12 000–14 000]	[15 000–18 000]
HIV incidence per 1000 population	0.08 [0.07–0.09]	0.1 [0.09–0.11]	0.12 [0.11–0.13]
AIDS-related deaths			
AIDS-related deaths (all ages)	1400	4700	6800
	[870–1800]	[3700–5700]	[5600–8000]
AIDS-related deaths (0-14)	<500	670	900
	[<500– <500]	[570–770]	[780–1000]
AIDS-related deaths (women, 15+)	<500	1300	2000
	[<200– <500]	[970–1600]	[1600–2400]
AIDS-related deaths (men, 15+)	640	2700	3900
	[<500–920]	[2100–3300]	[3100–4600]
People living with HIV			
People living with HIV (all ages)	68 000	130 000	190 000
	[59 000–77 000]	[110 000–150 000]	[160 000–210 000]
People living with HIV (0–14)	1800	4000	6100
	[1500–2100]	[3400–4600]	[5300–6900]
People living with HIV (women, 15+)	20 000	37 000	53 000
	[17 000–22 000]	[32 000–42 000]	[47 000–60 000]
People living with HIV (men, 15+)	47 000	87 000	130 000
	[40 000–54 000]	[76 000–100 000]	[110 000–140 000]
HIV prevalence (15–49)	<0.1 [<0.1–<0.1]	0.1 [<0.1–0.1]	0.1 [0.1–0.2]

I A \ A //	~	$\neg \land$			-
1 // ////	N N I	24 60 1			_ \
LAWS	2 AIN		-10	IJ I	

residence permits or for certain groups

Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	No
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	Yes, death penalty
Drug use or possession for personal use is an offence	Possession of drugs for personal use or drug use or consumption are not punished by laws or regulations
Criminalization of transgender people	Both criminalized and prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	Yes, for adolescents younger than 18 years
Spousal consent for married women to access sexual and reproductive health services	Yes
Mandatory HIV testing for marriage, work or	No

STIGMA AND DISCRIMINATION

Percentage of women and men aged 15–49 years who report discriminatory attitudes towards people living with HIV

Percentage of people living with HIV denied health services because of their HIV status in the last 12 months


Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their consent


VIOLENCE


Proportion of ever-married or partnered	2013	2018
women aged 15-49 years who experienced		
physical or sexual violence from a male		
intimate partner in the past 12 months	18	14.5


EXPENDITURES						
		Finar	ncing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total
Last available report: 2019	US\$ 5 578 386	US\$ 1 551 621	US\$ 0	US\$ 1 244 723	US\$ 0	US\$ 8 428 830

EPIDEMIC TRANSITION METRICS









75% HIV infections since 2010

Change in AIDSrelated deaths since 2010

405% prevalence ratio

13.44


Incidence: mortality ratio*

* The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

KEY POPULATIONS						
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners	
Estimated size of population				•••		
HIV prevalence	3.8%	3.7%	21.0%	5.5%	2.0%	
HIV testing and status awareness	72.8%	44.7%	47.1%**	69.1%**		
Antiretroviral therapy coverage	5.0%	0.8%	16.2%	10.2%		
Condom use	35.1%	22.4%	15.3%	24.4%		
Coverage of HIV prevention programmes	0.7%	1.2%	1.6%	1.1%		
Avoidance of health care because of stigma and discrimination						
Expenditures in US\$						

^{**} Programme data—not representative; includes people with negative results.

HIV TESTING AND TREATMENT CASCADE



All ages	21% [19–24%]	12% [11–14%] 22 947	% [%]
Children (0-14)	42% [36–48%]	31% [27–35%] 1 884	% [%]
Women (15+)	12% [11–14%]	9% [8–10%] 4 824	% [–%]
Men (15+)	24% [21–27%]	13% [11–15%] 16 239	% [–%]

	2010	2019
Percentage of pregnant women living with HIV accessing antiretroviral medicines	1% [1–2%]	12% [10–13%]
Final vertical transmission rate including during breastfeeding	46% [43–49%]	41% [39–44%]
Early infant diagnosis	1.2% [<1–1.4%]	2.8% [2.5–3.3%]

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	3800 [2500 –5400]
People living with HIV who started TB preventive therapy (2018)	
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV PREVENTION	
Adults aged 15+ years with unsuppressed viral load	
Knowledge of HIV prevention among young people aged 15–24 years (2017)	
— Women	1.8%
— Men	5.9%
Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years	
— Women	
— Men	
Women aged 15–49 years who have their demand for family planning satisfied by modern methods	
Men aged 15–49 years who are circumcised	Not applicable
Voluntary medical male circumcisions performed according to national standards	Not applicable
People who received PrEP at least once during the reporting period	
Harm reduction	

last injection (2016)	72.576
 Needles and syringes distributed per person who injects (2018) 	46

— Coverage of opioid substitution therapy

— Use of sterile injecting equipment at

Naloxone available (2019)

No — Safe injection rooms available (2019) No